Abstract
BackgroundRecent studies have highlighted the important role of long non-coding RNA SNHG16 in various human cancers. Here, we conducted a meta-analysis to investigate the effect of SNHG16 expression on clinicopathological features and prognosis in patients with different kinds of human cancers.MethodsWe performed a systematic search in electronic databases including PubMed, EMBASE, Cochrane Library and Web of Science, to investigate the potential association between SNHG16 expression and prognostic significance and clinical features in cancer patients. Odds ratios (ORs) or hazards ratios (HRs) with corresponding 95% confidence intervals (95% CIs) were pooled to estimate the prognosis value of SNHG16 by StataSE 15.0 software.ResultsA total of 16 eligible studies with 1299 patients were enrolled in our meta-analysis. The results revealed that increased expression level of SNHG16 was significantly associated with larger tumor size (OR: 3.357; 95% CI: 2.173–5.185; P < 0.001), advanced TNM stage (OR: 2.930; 95% CI: 1.522–5.640; P = 0.001) and poor histological grade (OR: 3.943; 95% CI: 1.955–7.952; P < 0.001), but not correlated with smoking status (P = 0.489), sex (P = 0.932), distant metastasis (P = 0.052), or lymph node metastasis (P = 0.155). Moreover, the pooled HR showed that elevated expression SNHG16 was associated with a significantly poorer overall survival (OS) (HR = 1.866, 95% CI: 1.571–2.216, P < 0.001). For the set of cancer types, high expression of SNHG16 was significantly associated with shorter OS in patients with cancers of the urinary system (HR: 2.523, 95% CI:1.540–4.133; P <0.001), digestive system (HR: 2.406, 95% CI:1.556–3.721; P <0.001), and other cancers (including glioma and non-small cell lung cancer) (HR: 1.786, 95% CI:1.406–2.267; P <0.001).ConclusionsLncRNA SNHG16 overexpression might serve as an unfavorable prognostic factor, which provides a basis for medical workers to evaluate the prognosis of patients and to help the decision-making process.
Highlights
Recent studies have highlighted the important role of long non-coding RNA Small nucleolar RNA host gene 16 (SNHG16) in various human cancers
Twelve types of human cancers were included in the meta-analysis, including bladder cancer, cervical cancer, colorectal cancer, esophageal squamous cell carcinoma, gastric cancer, glioma, hepatocellular carcinoma, non-small cell lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, and papillary thyroid cancer
The cut-off values for the expression level of SNGH16 were different in these studies, including the mean, median, and fold change compared with nontumor tissues, and in the study using In situ hybridization (ISH), strongly positive samples were defined as having high expression of SNGH16
Summary
Recent studies have highlighted the important role of long non-coding RNA SNHG16 in various human cancers. We conducted a meta-analysis to investigate the effect of SNHG16 expression on clinicopathological features and prognosis in patients with different kinds of human cancers. Cancer is a major disease that greatly endangers human health across the world. The incidence of cancer is increasing due to the growth and aging of the population, the intensification of industrialization and urbanization, and lifestyle modifications [1]. The burden of cancer cannot be ignored. Mounting evidence has documented that dysregulation of tumor-suppressor genes and oncogenes is associated with human cancers [2]. It is urgent to identify novel biomarkers for predicting the prognosis of patients with different types of cancer, which will improve their survival outcomes
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
